A. Desjardins

Allan H Friedman, James M Provenzale, R. McLendon, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy

P. Wen, T. Batchelor, D. Reardon, 2008, Expert opinion on biological therapy.

Molecularly targeted therapy for malignant glioma

D. Reardon, A. Desjardins, J. Vredenburgh, 2007, Cancer.

A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.

R. McLendon, A. Friedman, D. Bigner, 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

The Addition of Bevacizumab to Standard Radiation Therapy and Temozolomide Followed by Bevacizumab, Temozolomide, and Irinotecan for Newly Diagnosed Glioblastoma

A. Friedman, D. Bigner, H. Friedman, 2011, Clinical Cancer Research.

Single‐institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice

A. Friedman, E. Lipp, H. Friedman, 2019, Health science reports.

Bevacizumab and daily temozolomide for recurrent glioblastoma

H. Friedman, D. Reardon, A. Desjardins, 2012, Cancer.

Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data

W. Mason, S. Kesari, M. Trikha, 2021, Neuro-oncology advances.

ATIM-29. A PHASE 1 STUDY OF PF-06840003, AN ORAL INDOLE 2,3-DIOXYGENASE 1 (IDO1) INHIBITOR IN PATIENTS WITH MALIGNANT GLIOMAS

T. Cloughesy, D. Reardon, A. Lassman, 2017 .

Recurrent Glioblastoma Treated with Recombinant Poliovirus

John H. Sampson, Katherine B. Peters, Darell D. Bigner, 2018, The New England journal of medicine.

Tetanus toxoid and CCL3 improve DC vaccines in mice and glioblastoma patients

R. McLendon, A. Friedman, D. Bigner, 2015, Nature.

The Emerging Role of Anti-Angiogenic Therapy for Malignant Glioma†

D. Reardon, J. Rich, A. Desjardins, 2008, Current treatment options in oncology.

Interstitial chemotherapy with biodegradable BCNU (Gliadel®) wafers in the treatment of malignant gliomas

H. Friedman, A. Desjardins, D. Bota, 2007, Therapeutics and clinical risk management.

Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.

Allan H Friedman, R. McLendon, A. Friedman, 2009, Neuro-oncology.

Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.

Allan H Friedman, R. McLendon, A. Friedman, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma

D. Capper, A. Wick, S. Estrem, 2020, Investigational New Drugs.

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.

R. McLendon, H. Friedman, D. Reardon, 2010, Neuro-oncology.

Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy

T. Mikkelsen, M. Prados, P. Wen, 2017, Neuro-oncology.

Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma

R. McLendon, A. Friedman, D. Bigner, 2006, Clinical Cancer Research.

Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma

A. Friedman, D. Bigner, H. Friedman, 2008, Expert review of anticancer therapy.

Current available therapies and future directions in the treatment of malignant gliomas

D. Reardon, A. Desjardins, J. Vredenburgh, 2008, Biologics : targets & therapy.

Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas

A. Friedman, D. Bigner, J. Herndon, 2008, Clinical Cancer Research.

Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.

Yiting Cao, Mark W Dewhirst, M. Dewhirst, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models

R. McLendon, I. Pastan, D. Bigner, 2023, Science Translational Medicine.

Convection-enhanced delivery for high-grade glioma.

Jennifer H. Kang, A. Desjardins, 2021, Neuro-oncology practice.

Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas.

A. Friedman, H. Friedman, D. Reardon, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma

E. Lipp, H. Friedman, A. Desjardins, 2018, The oncologist.

Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas

E. Lipp, H. Friedman, D. Reardon, 2018, Journal of Neuro-Oncology.

Avastin: more questions than answers. . .

A. Desjardins, J. Sampson, 2012, Journal of neurosurgery.

Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma

R. McLendon, H. Friedman, D. Reardon, 2012, Journal of Neuro-Oncology.

Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

R. McLendon, H. Friedman, D. Reardon, 2011, Cancer.

Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high‐grade gliomas

P. Wen, T. Cloughesy, D. Schiff, 2016, Cancer.

Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas

R. McLendon, J. Provenzale, H. Friedman, 2007, Journal of Neuro-Oncology.

Assessment of physical functioning in recurrent glioma: preliminary comparison of performance status to functional capacity testing

A. Friedman, L. Jones, H. Friedman, 2009, Journal of Neuro-Oncology.

A cross sectional analysis from a single institution’s experience of psychosocial distress and health-related quality of life in the primary brain tumor population

S. Keir, E. Lipp, H. Friedman, 2017, Journal of Neuro-Oncology.

Neurofibromatosis type 2

D. Reardon, J. Rich, A. Desjardins, 2007, Neurology.

Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ)

H. Friedman, J. Kirkpatrick, A. Desjardins, 2016, Supportive Care in Cancer.

Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial

D. Tran, K. Fink, M. Mrugala, 2020, Clinical Cancer Research.

Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low‐grade glioma

R. McLendon, E. Lipp, H. Friedman, 2012, Cancer.

Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma

H. Friedman, D. Reardon, A. Desjardins, 2011, Journal of Neuro-Oncology.

A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma

T. Cloughesy, D. Reardon, A. Lassman, 2020, Investigational New Drugs.

Adjunctive perampanel for glioma-associated epilepsy☆

E. Lipp, H. Friedman, A. Desjardins, 2018, Epilepsy & Behavior Case Reports.

A prospective phase II study to determine the efficacy of GDC 0449 (vismodegib) in adults with recurrent medulloblastoma (MB): A Pediatric Brain Tumor Consortium study (PBTC 25B).

M. Prados, T. Curran, D. Ellison, 2013 .

Effects of low-dose naltrexone on quality of life in high-grade glioma patients: a placebo-controlled, double-blind randomized trial

E. Lipp, H. Friedman, A. Desjardins, 2021, Supportive Care in Cancer.

A Pilot Study of IL-2Rα Blockade during Lymphopenia Depletes Regulatory T-cells and Correlates with Enhanced Immunity in Patients with Glioblastoma

R. McLendon, A. Friedman, D. Bigner, 2012, PloS one.

Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.

R. McLendon, A. Friedman, D. Bigner, 2011, Blood.

Severe Adverse Immunologic Reaction in a Patient with Glioblastoma Receiving Autologous Dendritic Cell Vaccines Combined with GM-CSF and Dose-Intensified Temozolomide

A. Friedman, H. Friedman, A. Desjardins, 2014, Cancer Immunology Research.

Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy

D. Bigner, H. Friedman, D. Reardon, 2009, Cancer.

Phase 1 trial of temozolomide plus irinotecan plus O6‐benzylguanine in adults with recurrent malignant glioma

R. McLendon, H. Friedman, D. Reardon, 2009, Cancer.

Adjuvant Radiation in Older Patients With Glioblastoma: A Retrospective Single Institution Analysis

E. Lipp, H. Friedman, J. Kirkpatrick, 2021, Frontiers in Oncology.

Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.

A. Friedman, H. Friedman, D. Reardon, 2012, International journal of radiation oncology, biology, physics.

A Novel Method for Volumetric MRI Response Assessment of Enhancing Brain Tumors

John H. Sampson, Anthony F. Waller, Darell D. Bigner, 2011, PloS one.

Second primary cancers in long-term survivors of glioblastoma.

H. Friedman, A. Desjardins, J. Jackman, 2019, Neuro-oncology practice.

Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma

T. Mikkelsen, M. Prados, P. Wen, 2018, Neuro-oncology.

Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial.

O. Craciunescu, H. Friedman, Z. Chang, 2013, International journal of radiation oncology, biology, physics.

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma

E. Lipp, H. Friedman, D. Reardon, 2013, Cancer medicine.

Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination.

A. Friedman, D. Bigner, E. Lipp, 2015 .

Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models

S. Keir, D. Bigner, H. Friedman, 2018, Journal of Neuro-Oncology.

Bevacizumab fails to treat temporal paraganglioma: discussion and case illustration

R. McLendon, H. Friedman, D. Tucci, 2010, Journal of Neuro-Oncology.

Impact of health-related quality of life and fatigue on survival of recurrent high-grade glioma patients

W. Hornsby, H. Friedman, A. Desjardins, 2014, Journal of Neuro-Oncology.

A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab

H. Friedman, A. Desjardins, J. Vredenburgh, 2016, Therapeutics and clinical risk management.

Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma

R. McLendon, H. Friedman, D. Reardon, 2009, Journal of Neuro-Oncology.

Oncolytic polio virotherapy of cancer

D. Bigner, H. Friedman, D. Tyler, 2014, Cancer.

Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide

E. Lipp, H. Friedman, A. Desjardins, 2019, Supportive Care in Cancer.

Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations

I. Pastan, D. Bigner, A. Desjardins, 2019, Journal of Immunotherapy for Cancer.

CCR 20th Anniversary Commentary: Bevacizumab in the Treatment of Glioblastoma—The Progress and the Limitations

A. Desjardins, J. Vredenburgh, N. Mar, 2015, Clinical Cancer Research.

Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy

T. Mikkelsen, M. Prados, P. Wen, 2017, Neuro-oncology.

Primary brain tumor patients admitted to a US intensive care unit: a descriptive analysis

Jennifer H. Kang, E. Lipp, H. Friedman, 2021, CNS oncology.

107 Dose-Finding and Safety Study of an Oncolytic Polio/Rhinovirus Recombinant Against Recurrent Glioblastoma

A. Friedman, D. Bigner, H. Friedman, 2013 .

Dose-finding and safety study of an oncolytic polio/rhinovirus recombinant against recurrent glioblastoma.

A. Friedman, D. Bigner, H. Friedman, 2013 .

[Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study].

B. Chauffert, S. Taillibert, J. Honnorat, 2008, Revue neurologique.

The role of chemotherapy in the treatment of central neurocytoma

H. Friedman, J. Kirkpatrick, A. Desjardins, 2019, CNS oncology.

Intratumor childhood vaccine-specific CD4+ T-cell recall coordinates antitumor CD8+ T cells and eosinophils

D. Bigner, A. Desjardins, S. Nair, 2022, Journal for ImmunoTherapy of Cancer.

CTIM-10. REPRODUCIBILITY OF CLINICAL TRIALS USING CMV-TARGETED DENDRITIC CELL VACCINES IN PATIENTS WITH GLIOBLASTOMA

R. McLendon, D. Bigner, E. Thompson, 2021, Neuro-Oncology.

A change in the apparent diffusion coefficient after treatment with bevacizumab is associated with decreased survival in patients with recurrent glioblastoma multiforme.

D. Barboriak, H. Friedman, A. Desjardins, 2012, The British journal of radiology.

Repeatability of Automated Image Segmentation with BraTumIA in Patients with Recurrent Glioblastoma

D. Barboriak, A. Desjardins, J. Vredenburgh, 2021, American Journal of Neuroradiology.

Bevacizumab, temozolomide, and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly-diagnosed glioblastoma multiforme (GBM).

H. Friedman, D. Reardon, J. Kirkpatrick, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Complementary and integrative health interventions and their association with health-related quality of life in the primary brain tumor population.

E. Lipp, H. Friedman, A. Desjardins, 2019, Complementary therapies in clinical practice.

CTIM-21. PEPTIDE VACCINE DIRECTED TO CMV pp65 FOR TREATMENT OF RECURRENT MALIGNANT GLIOMA AND MEDULLOBLASTOMA IN CHILDREN AND YOUNG ADULTS: PRELIMINARY RESULTS OF A PHASE I TRIAL

E. Lipp, M. Khasraw, A. Desjardins, 2020, Neuro-Oncology.

Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma.

A. Friedman, L. Jones, W. Hornsby, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EPCT-01. A NOVEL PEPTIDE VACCINE DIRECTED TO CMV PP65 FOR TREATMENT OF RECURRENT MALIGNANT GLIOMA AND MEDULLOBLASTOMA IN CHILDREN AND YOUNG ADULTS: PRELIMINARY RESULTS OF A PHASE I TRIAL

E. Thompson, E. Lipp, M. Khasraw, 2021, Neuro-Oncology.

Bevacizumab and daily temozolomide for recurrent glioblastoma multiforme (GBM)

H. Friedman, D. Reardon, J. Rich, 2008 .

Vaccine Therapy, Oncolytic Viruses, and Gliomas.

H. Friedman, A. Desjardins, G. Vlahović, 2016, Oncology.

QOLP-29. MINDFULNESS MEDITATION PRACTICE IN MALIGNANT GLIOMA PATIENTS THROUGHOUT CONCOMITANT RADIATION AND TEMOZOLOMIDE: A FEASIBILITY STUDY

E. Lipp, H. Friedman, A. Desjardins, 2019, Neuro-Oncology.

Phase II trial of bevacizumab plus erlotinib for patients with recurrent malignant gliomas: Final results.

R. McLendon, H. Friedman, D. Reardon, 2010 .

Phase II study of bevacizumab plus erlotinib for recurrent malignant gliomas.

A. Friedman, H. Friedman, D. Reardon, 2009, Journal of Clinical Oncology.

Bevacizumab (BEV) in combination with temozolomide (TMZ) and radiation therapy (XRT) followed by BEV, TMZ, and irinotecan for newly diagnosed glioblastoma multiforme (GBM).

H. Friedman, D. Reardon, J. Kirkpatrick, 2010 .

NEURO/MEDICAL ONCOLOGY

Scott N. Hwang, Katrina H. Smith, Susan M. Chang, 2013 .

Phase II study to evaluate the efficacy and safety of rilotumumab and bevacizumab (BEV) in subjects with recurrent malignant glioma (MG).

E. Lipp, H. Friedman, A. Desjardins, 2012 .

Spiritual well-being and its association with health-related quality of life in primary brain tumor patients.

E. Lipp, H. Friedman, A. Desjardins, 2021, Neuro-oncology practice.

Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.

J. Herndon, E. Lipp, H. Friedman, 2019, Journal of Clinical Oncology.

Phase I study of the intratumoral administration of an oncolytic polio/rhinovirus recombinant (PVSRIPO) in recurrent glioblastoma (GBM).

A. Friedman, D. Bigner, H. Friedman, 2014 .

Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM).

D. Hafler, H. Friedman, D. Reardon, 2014 .

Bevacizumab therapy for glioblastoma: a passionate discussion.

H. Friedman, A. Desjardins, 2014, CNS oncology.

IMMU-26. SAFETY AND EFFICACY OF PVSRIPO IN RECURRENT GLIOBLASTOMA: LONG-TERM FOLLOW-UP AND INITIAL MULTICENTER RESULTS

P. Wen, D. Bigner, N. Butowski, 2021, Neuro-Oncology.

Phase I trial of imatinib mesylate, hydroxyurea and vatalanib for patients with recurrent glioblastoma multiforme (GBM)

H. Friedman, D. Reardon, J. Rich, 2007 .

Correcting the drug development paradigm for glioblastoma requires serial tissue sampling.

R. Verhaak, P. Wen, T. Cloughesy, 2023, Nature Network Boston.

Performance of a nomogram for IDH-wild-type glioblastoma patient survival in an elderly cohort.

R. McLendon, E. Lipp, H. Friedman, 2019, Neuro-oncology advances.

LUMINOS-101: Phase 2 study of PVSRIPO with pembrolizumab in recurrent glioblastoma.

P. Wen, W. Curry, N. Butowski, 2021 .

ACTR-40. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, ndGBM): FULL ENROLLMENT RESULTS

R. Stupp, W. Mason, S. Kesari, 2018, Neuro-Oncology.

Intratumor childhood vaccine-specific CD4+ T-cell recall coordinates antitumor CD8+ T cells and eosinophils

D. Bigner, A. Desjardins, S. Nair, 2023, Journal for ImmunoTherapy of Cancer.

Bevacizumab and daily temozolomide for recurrent glioblastoma

H. Friedman, D. Reardon, A. Desjardins, 2012, Cancer.

Phase II trial of Gliadel plus O6-benzylguanine (O6-BG) for patients with recurrent glioblastoma multiforme.

A. Friedman, H. Friedman, D. Reardon, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Emerging Role of Anti-Angiogenic Therapy for Malignant Glioma†

D. Reardon, J. Rich, A. Desjardins, 2008, Current treatment options in oncology.

Current available therapies and future directions in the treatment of malignant gliomas

A. Desjardins, J. Vredenburgh, David A. Reardon, 2008 .

Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.

R. McLendon, A. Friedman, K. Aldape, 2011, Neuro-oncology.

Recurrent Glioblastoma Treated with Recombinant Poliovirus

William T. Harrison, R. McLendon, A. Friedman, 2018, The New England journal of medicine.

Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial.

R. McLendon, E. Thompson, E. Lipp, 2023, The Lancet. Child & adolescent health.

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study

R. McLendon, D. Bigner, H. Friedman, 2009, British Journal of Cancer.

Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.

R. McLendon, A. Friedman, D. Bigner, 2011, Blood.

Everolimus tablets for patients with subependymal giant cell astrocytoma

H. Friedman, D. Reardon, A. Desjardins, 2011, Expert opinion on pharmacotherapy.

Interstitial chemotherapy with biodegradable BCNU (Gliadel®) wafers in the treatment of malignant gliomas

H. Friedman, A. Desjardins, D. Bota, 2007, Therapeutics and clinical risk management.

Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy

D. Bigner, H. Friedman, D. Reardon, 2009, Cancer.

Evolocumab as an immunomodulator in glioma: A window of opportunity trial evaluating PCSK9 inhibition to enhance surface MHC-I on tumor

R. McLendon, A. Desjardins, P. Fecci, 2024, medRxiv.

Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low‐grade glioma

R. McLendon, E. Lipp, H. Friedman, 2012, Cancer.

Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls.

A. Friedman, D. Bigner, E. Lipp, 2016 .

A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine

A. Desjardins, M. Glas, D. Blumenthal, 2024, Nature communications.